Intertoe Squamous Cell Carcinoma Developed in a Patient with Rheumatoid Arthritis under Etanercept Therapy.
Efstathios RallisVasiliki-Kalliopi BourniaConstantinos VerrosAlexios IliopoulosPublished in: Case reports in medicine (2015)
The use of tumor necrosis factor-α (TNF-α) inhibitors in the treatment of various inflammatory conditions has altered the field of medical therapeutics. Squamous cell carcinoma is the second most common cancer of the skin, usually affecting sun-exposed areas of the body. We present here the case of a 75-year-old woman with rheumatoid arthritis, who developed an intertoe squamous cell carcinoma (SCC) of the right foot. According to her history, she received etanercept and methotrexate for 5 years for rheumatoid arthritis. The rare localization of this cancer could suggest a possible linkage of the malignancy to the chronic intake of anti-TNF-α treatment. This is the first reported case of an interdigital SCC developed under the use of an anti-TNF-α agent.
Keyphrases
- rheumatoid arthritis
- squamous cell carcinoma
- disease activity
- ankylosing spondylitis
- papillary thyroid
- interstitial lung disease
- lymph node metastasis
- rheumatoid arthritis patients
- locally advanced
- oxidative stress
- body mass index
- high dose
- small molecule
- genome wide
- juvenile idiopathic arthritis
- bone marrow
- low dose
- replacement therapy
- idiopathic pulmonary fibrosis
- antiretroviral therapy
- smoking cessation
- drug induced